Cargando…
A Pilot Trial for Prevention of Hepatitis C Virus Transmission From Donor to Organ Transplant Recipient With Short-Course Glecaprevir/Pibrentasvir
A 7-day course of glecaprevir/pibrentasvir started in the preoperative period prevented transmission of hepatitis C virus (HCV) from viremic donors to 10 HCV-negative recipients (2 heart, 1 lung, 6 kidney, 1 heart/kidney) with 100% sustained virological response at 12 weeks.
Autores principales: | Ramirez-Sanchez, Claudia, Kozuch, Jade, Shah, Mita M, Berumen, Jennifer, Mekeel, Kristin, Schnickel, Gabriel, Taremi, Mahnaz, Golts, Eugene, Afshar, Kamyar, Adler, Eric, Pretorius, Victor, Aslam, Saima |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679803/ https://www.ncbi.nlm.nih.gov/pubmed/36420058 http://dx.doi.org/10.1093/ofid/ofac550 |
Ejemplares similares
-
Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan
por: Huang, Chung-Feng, et al.
Publicado: (2021) -
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection
por: Liu, Xiaoqing, et al.
Publicado: (2021) -
Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy
por: Cotter, Thomas G, et al.
Publicado: (2019) -
Risk Factors of Glecaprevir/Pibrentasvir-Induced Liver Injury and Efficacy of Ursodeoxycholic Acid
por: Tamai, Hideyuki, et al.
Publicado: (2023) -
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection
por: Reau, Nancy, et al.
Publicado: (2018)